Skip to main content
Premium Trial:

Request an Annual Quote

Axxam, Polyphor Team on Drug Screening

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Italian drug screening technologies company Axxam will collaborate with Swiss firm Polyphor on ion channel-based research, the firms said today.

The partners will use their respective drug discovery and screening platforms to identify drug candidates for therapeutic areas including pain, inflammation, and metabolic disorders.

Under the agreement, Axxam will provide its Hit Discovery platforms and capabilities and Polyphor will provide its screening technology and its knowledge in medicinal chemistry, drug discovery, and development. Polyphor's screening tools include the Protein Epitope Mimetics (PEM) technology, and it has built a PEM-based drug portfolio aimed at moving candidates through clinical trials.

"We believe that our unique cooperation and the complementary skill sets of both companies will offer a valuable alternative for innovation in the demanding field of ion channel based drugs and will industrialize the process for the generation of novel drugs for high medical needs," Axxam CEO and Chairman Stefan Lohmer said in a statement.

Axxam is situated in the San Raffaele Biomedical Science Park in Milan.

The Scan

Billions for Antivirals

The US is putting $3.2 billion toward a program to develop antivirals to treat COVID-19 in its early stages, the Wall Street Journal reports.

NFT of the Web

Tim Berners-Lee, who developed the World Wide Web, is auctioning its original source code as a non-fungible token, Reuters reports.

23andMe on the Nasdaq

23andMe's shares rose more than 20 percent following its merger with a special purpose acquisition company, as GenomeWeb has reported.

Science Papers Present GWAS of Brain Structure, System for Controlled Gene Transfer

In Science this week: genome-wide association study ties variants to white matter stricture in the brain, and more.